2nd Circ. Revives Pfizer Securities Suit Over Drug Risks

By Ed Beeson (April 12, 2016, 11:04 AM EDT) -- The Second Circuit on Tuesday revived a securities class action against Pfizer over the alleged hidden health risks of two of its drugs, saying the lower court had improperly excluded an expert who was set to testify on behalf of the plaintiffs and had earlier erred when it granted the drugmaker summary judgment....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.

A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!